Copy

Welcome

Welcome to the second issue of the ROADMAP newsletter!

 
 
This second newsletter provides you with up to date information on the project's latest progress. The Consortium is busier than ever: ROADMAP partners presented and discussed innovation, value and challenges for health technology assessment (HTA) at the HTAi conference in Rome; the ethics team presented a first poster (at the Neuroethics Network) in Paris, the identification team submitted its first key deliverable to IMI and we all met for the third time in Barcelona to jointly discuss progress and plans for the future.

You also have the opportunity to hear from our colleague Antje Hottgenroth, who provides us with the industry perspective on the work with real world data. Last but not least, I am very delighted to announce that our Consortium has grown even bigger and to welcome the  "Leiden University" as a new full partner.

Enjoy!
 

Frederic De Reydet De Vulpillieres





Frédéric De Reydet De Vulpillieres
Project Leader (on behalf of EFPIA) and WorldWide Market Access Director NS at Novartis
 

Pick of the season

19 June: Meet the ROADMAP team at the HTAi conference 2017


On 20 June, four speakers from the ROADMAP Consortium (Jean Georges, Ron Handels, Jacoline Bouvy and Catherine Reed) held a 90 minute panel session, moderated by Michael Happich, on "The state of Alzheimer’s disease in Europe – innovation, value and challenges for HTA" at the HTAi conference 19-21 June, in Rome (Italy).
Read more

Latest News

 

21 June: The ROADMAP ethics team welcomes Andrew Turner as the new co-lead and presents first poster at Neuroethics network


On 21 June, Work Package 8 “Ethical, Legal and Social Implications (ELSI)” presented a poster on "Overcoming ethical issues in sharing real world evidence in Alzheimer’s disease: The ROADMAP Project" at the Neuroethics Network in Paris (France). WP8 also welcomes Andrew Turner as academic co-lead to WP8, and is proud to announce that they recently submitted their deliverable: "Review of ELSI issues in RWE approach" to the Innovative Medicines Initiative.
Read more
 

8 June: ROADMAP makes progress on regulatory and HTA engagement

 


On 8 May, Work Package 6 “Regulatory and HTA engagement” held the first teleconference of the newly established expert advisory group (EXAG). The meeting was chaired by Jacoline Bouvy (NICE) and involved all seven EXAG members from HTA and regulatory agencies across Europe, as well as Work Package 6 representatives.
Read more
 

15 May: An overview of potental RWE data sources is submitted as a new deliverable to IMI


Work Package 3 (WP3) “Identification, mapping and integration or RWE” has submitted its first report, called “D3.1 Initial Overview of potential data sources with Real World Evidence (RWE) data in Europe” to the Innovative Medicines Initiative (IMI). This is not the first project deliverable, but is the first deliverable for WP3 and constitutes an important milestone for the project.
Read more

Scientific involvement

We talk with Antje Hottgenroth about her involvement in ROADMAP
 

Antje Hottgenroth
Antje Hottgenroth is a biologist with a doctorate in Natural Sciences. She held several positions within the German affiliate, the regional and currently corporate company organisation Eli Lilly.

During her recent Data Scientist role, she contributed to several company projects for optimisation of real world evidence (RWE) research and building of a RWE/real world data (RWD) knowledge repository.

She is also industry co-lead of Work Package 3: "Identification, mapping and integration of RWE" and will give us an insight into what that means. In this interview Antje Hottgenroth tells us about her role in ROADMAP, her expectations and challenges. We also we get a short insight into the world of real world data and the work her team is undertaking for the ROADMAP project.
Read more

Events

12 June: ROADMAP holds 3rd General Assembly Meeting in Barcelona


On 12 and 13 June (Barcelona, Spain), the ROADMAP project gathered for their 3rd General Assembly Meeting (GAM). The meeting was chaired by John Gallacher (Project Coordinator; The Chancellor, Masters and Scholars of the University of Oxford) and Frédéric de Reydet de Vulpillieres (Project Leader, Novartis on behalf of EFPIA). The aim of the meeting was to provide updates on the progress of the different Work Packages, discuss the research questions and how the specifications and amendments of those influence the specific plans of the WPs in the next three months.
Read more
@IMI2_ROADMAP
http://roadmap-alzheimer.org/
info@roadmap-alzheimer.org

Copyright © 2017 ROADMAP, All rights reserved.

Our mailing address is:
info@roadmap-alzheimer.org
Sign up for our list!
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

 
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
ROADMAP · Alzheimer Europe · 14 rue Dicks · Luxembourg L-1417 · Luxembourg

Email Marketing Powered by Mailchimp